Immune Recovery After Starting ART in HIV-infected Patients Presenting and Not Presenting with Tuberculosis in South Africa

Overview

Journal J Acquir Immune Defic Syndr

Specialty Infectious Diseases

Date 2013 Feb 1

PMID 23364513

Citations 12

Authors

Michael Schomaker

Matthias Egger

Mhairi Maskew

Daniela Garone

Hans Prozesky

Christopher J Hoffmann

Andrew Boulle

Lukas Fenner

Affiliations

Soon will be listed here.

Abstract

We studied the immune response after starting antiretroviral treatment (ART) in 15,646 HIV-infected patients with or without tuberculosis (TB) at presentation in 3 ART programs in South Africa between 2003 and 2010. Patients presenting with TB had similar increases in CD4 cells compared with all other patients (adjusted difference 4.9 cells/µL per 6 months, 95% confidence interval: 0.2 to 9.7). Younger age, advanced clinical stage, female sex, and lower CD4 cell count at ART start were all associated with steeper CD4 slopes. In South Africa, HIV-infected patients presenting with TB experience immune recovery after starting ART that is no worse than in other patients.

Citing Articles

Persistent advanced HIV disease in rural KwaZulu-Natal, South Africa: Trends, characteristics, and the urgent need for targeted interventions.

Kitenge M, Fatti G, Eshun-Wilson I, Nyasulu P PLoS One. 2025; 20(2):e0317674.

PMID: 39965033 PMC: 11835316. DOI: 10.1371/journal.pone.0317674.

The prognosis for delayed immune recovery in HIV-infected children might be associated with pre-cART CD4 T cell count irrespective of co-infection with tuberculosis.

Ogunshola F, Khan R, Ghebremichael M BMC Res Notes. 2025; 18(1):6.

PMID: 39773670 PMC: 11707843. DOI: 10.1186/s13104-024-07032-y.

The Prognosis for Delayed Immune Recovery in HIV-Infected Children might be Associated with Pre-cART CD4 + T cell Count Irrespective of Co-Infection with Tuberculosis.

Ogunshola F, Khan R, Ghebremichael M Res Sq. 2024; .

PMID: 38699317 PMC: 11065074. DOI: 10.21203/rs.3.rs-4243586/v1.

Paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome in initiating ART among HIV-Infected patients in China-risk factors and management.

Yang H, Liu Q, Wu Y, He K, Zeng Q, Liu M BMC Infect Dis. 2024; 24(1):5.

PMID: 38166781 PMC: 10759358. DOI: 10.1186/s12879-023-08897-3.

Rapid antiretroviral therapy initiation in patients with advanced HIV disease: 6-month outcomes of an observational cohort evaluation in Lesotho.

Tiam A, Paulin H, Machekano R, Oboho I, Agyemang E, Mugyenyi F PLoS One. 2023; 18(10):e0292660.

PMID: 37819941 PMC: 10566720. DOI: 10.1371/journal.pone.0292660.

References

Sulkowski M, Chaisson R, Karp C, Moore R, Margolick J, Quinn T . The effect of acute infectious illnesses on plasma human immunodeficiency virus (HIV) type 1 load and the expression of serologic markers of immune activation among HIV-infected adults. J Infect Dis. 1998; 178(6):1642-8. DOI: 10.1086/314491. View

Cingolani A, Lepri A, Castagna A, Goletti D, De Luca A, Scarpellini P . Impaired CD4 T-cell count response to combined antiretroviral therapy in antiretroviral-naive HIV-infected patients presenting with tuberculosis as AIDS-defining condition. Clin Infect Dis. 2011; 54(6):853-61. DOI: 10.1093/cid/cir900. View

Brinkhof M, Egger M, Boulle A, May M, Hosseinipour M, Sprinz E . Tuberculosis after initiation of antiretroviral therapy in low-income and high-income countries. Clin Infect Dis. 2007; 45(11):1518-21. PMC: 3687541. DOI: 10.1086/522986. View

Kohler P, Chung M, McGrath C, Benki-Nugent S, Thiga J, John-Stewart G . Implementation of free cotrimoxazole prophylaxis improves clinic retention among antiretroviral therapy-ineligible clients in Kenya. AIDS. 2011; 25(13):1657-61. PMC: 3383052. DOI: 10.1097/QAD.0b013e32834957fd. View

Morris A, Ben Beard C, Huang L . Update on the epidemiology and transmission of Pneumocystis carinii. Microbes Infect. 2002; 4(1):95-103. DOI: 10.1016/s1286-4579(01)01514-3. View

Boulle A, Van Cutsem G, Hilderbrand K, Cragg C, Abrahams M, Mathee S . Seven-year experience of a primary care antiretroviral treatment programme in Khayelitsha, South Africa. AIDS. 2010; 24(4):563-72. DOI: 10.1097/QAD.0b013e328333bfb7. View

Morris L, Martin D, Bredell H, Nyoka S, Sacks L, Pendle S . Human immunodeficiency virus-1 RNA levels and CD4 lymphocyte counts, during treatment for active tuberculosis, in South African patients. J Infect Dis. 2003; 187(12):1967-71. DOI: 10.1086/375346. View

Fenner L, Forster M, Boulle A, Phiri S, Braitstein P, Lewden C . Tuberculosis in HIV programmes in lower-income countries: practices and risk factors. Int J Tuberc Lung Dis. 2011; 15(5):620-7. PMC: 3140103. DOI: 10.5588/ijtld.10.0249. View

Lawn S, Myer L, Bekker L, Wood R . Burden of tuberculosis in an antiretroviral treatment programme in sub-Saharan Africa: impact on treatment outcomes and implications for tuberculosis control. AIDS. 2006; 20(12):1605-12. DOI: 10.1097/01.aids.0000238406.93249.cd. View

10.

Lawn S, Bekker L, Wood R . How effectively does HAART restore immune responses to Mycobacterium tuberculosis? Implications for tuberculosis control. AIDS. 2005; 19(11):1113-24. DOI: 10.1097/01.aids.0000176211.08581.5a. View

11.

Lawn S, Wilkinson R, Lipman M, Wood R . Immune reconstitution and "unmasking" of tuberculosis during antiretroviral therapy. Am J Respir Crit Care Med. 2008; 177(7):680-5. PMC: 2277208. DOI: 10.1164/rccm.200709-1311PP. View

12.

Grant A, Fielding K, Charalambous S, Chaisson R, Churchyard G . Why have trials of isoniazid preventive therapy among people with HIV infection not demonstrated an effect on mortality?: did close examination of the trees obscure our view of the wood?. AIDS. 2010; 24 Suppl 5:S15-8. DOI: 10.1097/01.aids.0000391011.40892.ff. View

13.

Goletti D, Weissman D, Jackson R, Graham N, Vlahov D, Klein R . Effect of Mycobacterium tuberculosis on HIV replication. Role of immune activation. J Immunol. 1996; 157(3):1271-8. View

14.

Havlir D, Barnes P . Tuberculosis in patients with human immunodeficiency virus infection. N Engl J Med. 1999; 340(5):367-73. DOI: 10.1056/NEJM199902043400507. View

15.

Wallis R, Vjecha M, Okwera A, Byekwaso F, Nyole S, Kabengera S . Influence of tuberculosis on human immunodeficiency virus (HIV-1): enhanced cytokine expression and elevated beta 2-microglobulin in HIV-1-associated tuberculosis. J Infect Dis. 1993; 167(1):43-8. DOI: 10.1093/infdis/167.1.43. View

16.

Whalen C, Nsubuga P, Okwera A, Johnson J, Hom D, Michael N . Impact of pulmonary tuberculosis on survival of HIV-infected adults: a prospective epidemiologic study in Uganda. AIDS. 2000; 14(9):1219-28. PMC: 2869086. DOI: 10.1097/00002030-200006160-00020. View

17.

Lawn S, Shattock R, Acheampong J, Lal R, Folks T, Griffin G . Sustained plasma TNF-alpha and HIV-1 load despite resolution of other parameters of immune activation during treatment of tuberculosis in Africans. AIDS. 1999; 13(16):2231-7. DOI: 10.1097/00002030-199911120-00005. View

18.

Balestre E, Eholie S, Lokossue A, Sow P, Charurat M, Minga A . Effect of age on immunological response in the first year of antiretroviral therapy in HIV-1-infected adults in West Africa. AIDS. 2012; 26(8):951-7. PMC: 3704338. DOI: 10.1097/QAD.0b013e3283528ad4. View

19.

Egger M, Ekouevi D, Williams C, Lyamuya R, Mukumbi H, Braitstein P . Cohort Profile: the international epidemiological databases to evaluate AIDS (IeDEA) in sub-Saharan Africa. Int J Epidemiol. 2011; 41(5):1256-64. PMC: 3465765. DOI: 10.1093/ije/dyr080. View

20.

Lancioni C, Mahan C, Johnson D, Walusimbi M, Chervenak K, Nalukwago S . Effects of antiretroviral therapy on immune function of HIV-infected adults with pulmonary tuberculosis and CD4+ >350 cells/mm3. J Infect Dis. 2011; 203(7):992-1001. PMC: 3068037. DOI: 10.1093/infdis/jiq141. View